© Reuters.
VANCOUVER, Canada – Clearmind Medicine Inc. (NASDAQ:CMND), (CSE:CMND), (FSE:CWY), a biotech company specializing in psychedelic-derived therapeutics, announced today that the Ministry of Health of Israel has granted approval for the company’s phase I/IIa clinical trial. This trial will investigate the safety and efficacy of CMND-100, an oral capsule containing the company’s proprietary molecule MEAI (5-methoxy-2-aminoindane), for patients with alcohol use disorder (AUD).
The study, led by Prof. Mark Weiser, M.D., at the Sheba Medical Center in Ramat Gan, Israel, will assess the tolerability, safety, and pharmacokinetics of CMND-100 in both healthy volunteers and subjects with AUD. The clinical trial also includes sites in the United States at the Yale School of Medicine’s Department of Psychiatry and the Johns Hopkins University School of Medicine.
CMND-100’s primary endpoint is to determine the tolerable dose and characterize the safety profile of single and repeated doses in study participants. Secondary objectives include the evaluation of preliminary efficacy in reducing drinking patterns and cravings in individuals with moderate-to-severe AUD.
The active ingredient in CMND-100, MEAI, is a psychoactive substance that is non-hallucinogenic and has shown potential in preclinical studies to reduce the desire to consume alcohol. MEAI acts on the serotonergic system, which is implicated in the regulation of alcohol intake and dependence, and interacts with alpha-2-adrenergic receptors and monoamine transporters related to dopamine, norepinephrine, and serotonin.
This approval marks a significant milestone for Clearmind as it transitions to a clinical-stage pharmaceutical company. Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, expressed enthusiasm for the trial’s potential to address the global need for innovative treatments for addiction.
Clearmind aims to develop regulated medicines from psychedelic-based compounds and holds an intellectual property portfolio of fifteen patent families. The company’s stock is traded on several exchanges, including Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange.
The information in this article is based on a press release statement from Clearmind Medicine Inc.
InvestingPro Insights
Clearmind Medicine Inc. (NASDAQ:CMND) has been navigating challenging market conditions, as reflected in its recent financial metrics and stock performance. As of the last twelve months ending in Q4 2023, the company holds a market capitalization of just $5.81 million, indicative of its small-cap status in the biotech sector. Despite the excitement surrounding the clinical trial approval, it’s important to note that the company’s stock has experienced significant volatility, with a 37.78% return over the last week and an impressive 87.88% return over the last month. These swings in stock price are not uncommon for companies in the early stages of drug development, where investor sentiment can shift rapidly based on clinical trial results and regulatory news.
Investors should also be aware that Clearmind Medicine’s price/book ratio as of the last twelve months stands at 5.93, which suggests that the stock is trading at a premium relative to the company’s book value. This could be a point of consideration for value-oriented investors. Moreover, the company does not pay a dividend to shareholders, which is typical for growth-focused biotech companies that prefer to reinvest any earnings into research and development.
For those interested in a deeper dive into the company’s financial health and future prospects, InvestingPro offers additional insights. Notably, Clearmind Medicine holds more cash than debt on its balance sheet, which is a positive sign for its financial stability. However, the company is quickly burning through cash and has not been profitable over the last twelve months, which are common challenges for early-stage biotech companies that are yet to commercialize their products.
For potential investors, it’s crucial to weigh the company’s recent advancements against its financial metrics and market performance. To access a comprehensive list of InvestingPro Tips, including 13 additional tips for Clearmind Medicine Inc., visit InvestingPro. Don’t forget to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing a valuable resource for those looking to make an informed investment decision.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
This story originally appeared on Investing
